Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | CCKBR | P32239 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584588 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL10915007 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL5240188 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL392779 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL4543871 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL27685085 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL6948425 | 0.77 | KMT2A (0.43) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL1532332 | 0.74 | CYP11B1 (0.41) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL30340414 | 0.74 | CYP11B1 (0.38) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 | |
| SCHEMBL8188378 | 0.73 | KMT2A (0.46) | CYP11B1CYP11B2KMT2AKCNN4KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12324845-B2 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250161500-A1 | LIGANDS FOR IMAGING CARDIAC INNERVATION | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250059231-A1 | Protease inhibitors | PROTINHI B.V. (NL) | 2025-02-20 | — | — | US | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052636-A1 | PROTEASE INHIBITORS | PROTINHI B.V. (NL) | 2023-04-06 | — | — | WO | disclosed |
| US-20220288243-A1 | LIGANDS FOR IMAGING CARDIAC INNERVATION | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11241509-B2 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2474525-B1 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2474523-B1 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING INC (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-1998043962-A1 | HETEROCYCLIC INTEGRIN INHIBITOR PRODRUGS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5760029-A | TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5760028-A | TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5585360-A | THROMBIN INHIBITORS | ADIR ET COMPAGNIE (FR) | 1996-12-17 | — | — | US | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0688788-A1 | Boronic acid peptide derivatives having protease inhibiting activity, process for preparation thereof and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1995-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288243-A1 | LIGANDS FOR IMAGING CARDIAC INNERVATION | TNNT2, PNMT, TNNC1 | CYP11B1 1883/4885CYP11B2 1810/4885KMT2A 569/4885 |
| US-11241509-B2 | Ligands for imaging cardiac innervation | TNNT2, PNMT, TNNC1 | CYP11B1 1893/4885CYP11B2 1854/4885KMT2A 520/4885 |
| US-20250059231-A1 | Protease inhibitors | PREP, DNPEP, TMPRSS15 | CYP11B1 4819/4885CYP11B2 4860/4885KMT2A 2049/4885 |
| US-20250161500-A1 | LIGANDS FOR IMAGING CARDIAC INNERVATION | TNNT2, PNMT, TNNC1 | CYP11B1 1883/4885CYP11B2 1810/4885KMT2A 569/4885 |
| US-12324845-B2 | Ligands for imaging cardiac innervation | CHRNB4, RXFP4, RXFP3 | CYP11B1 2054/4885CYP11B2 1984/4885KMT2A 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.